Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/29/2025 | Buy → Neutral | H.C. Wainwright | |
8/28/2025 | Buy → Neutral | Guggenheim | |
12/2/2024 | Buy → Neutral | Chardan Capital Markets | |
3/27/2024 | $50.00 | Neutral → Buy | BTIG Research |
2/15/2024 | $3.00 | Neutral → Buy | Chardan Capital Markets |
1/25/2024 | Neutral → Buy | Guggenheim | |
12/27/2023 | $5.00 | Equal Weight → Overweight | CapitalOne |
8/31/2023 | $5.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral
Guggenheim downgraded Outlook Therapeutics from Buy to Neutral
Chardan Capital Markets downgraded Outlook Therapeutics from Buy to Neutral
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT For more inf
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. In the FDA's recently issued CRL, although the Agency acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoint
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat
8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
SCHEDULE 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
3 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. "On behalf of our management team
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat
First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net
LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz
SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)